Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

Inclusion Criteria:

- Subjects who are between 20 and 45 years and of age, inclusive at the time of signing
the informed consent form.

- Japanese, defined as being born in Japan, having four ethnic Japanese grandparents,
holding a Japanese passport or identity papers and being able to speak Japanese, and
that lifestyle including diet has not changed significantly since leaving Japan.
Japanese subjects should also have lived outside Japan for less than 10 years.

- Caucasian subjects as defined as an individual having four grandparents who are all
descendants of the original peoples of Europe.

- Healthy as determined by the investigator or medically qualified designee based on a
medical evaluation including medical history, physical examination, laboratory tests
and cardiac monitoring obtained at the screening visit.

- A subject with a clinical abnormality or laboratory parameter(s) which is/are not
specifically listed in the inclusion or exclusion criteria, outside the reference
range for the population being studied may be included only if the investigator in
consultation with the medical monitor agree and document that the finding is unlikely
to introduce additional risk factors and will not interfere with the study
procedures.

- Body weight >=43 kilograms (kg) and body mass index (BMI) within the range 17-29.9
kilogram per square meter (kg/m^2) (inclusive).

- Female subjects- A female subject is eligible to participate if she is: A female of
non-productive potential secondary to a personal history of a hysterectomy or tubal
sterilization procedure.

A female of reproductive potential who is not pregnant (as confirmed by a negative urine
or serum human chorionic gonadotropin [hCG] test), not lactating, and agrees to follow one
of the options listed in protocol. Contraception requirement for female subjects from 28
days prior to the first dose of study treatment and until completion of the follow-up
visit.

- Capable of giving signed informed consent as described in protocol which includes
compliance with the requirements and restrictions listed in the consent form and in
this protocol.

Exclusion Criteria:

- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin >1.5x upper limit
of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is
fractionated and direct bilirubin <35%).

- Current or chronic history of liver disease, or known hepatic or biliary
abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)

- QT duration corrected (QTc) >450 milliseconds (msec) NOTES: The QTc is the QT
interval corrected for heart rate according to Bazett's formula (QTcB), QT duration
corrected for heart rate by Fridericia's formula (QTcF), and/or another method,
machine-read or manually over-read.

The specific formula that will be used to determine eligibility and discontinuation for an
individual subject should be determined prior to initiation of the study. In other words,
several different formulae cannot be used to calculate the QTc for an individual subject
and then the lowest QTc value used to include or discontinue the subject from the trial.

- Subjects must abstain from taking prescription or non-prescription drugs (including
vitamins and dietary or herbal supplements) except occasional usage of acetaminophen,
within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives
(whichever is longer) prior to the first dose of investigational product until
completion of the follow-up visit, unless in the opinion of the investigator and
GlaxoSmithKline (GSK) medical monitor the medication will not interfere with the
study.

- History of regular alcohol consumption within 6 months of the study defined as: An
average weekly intake of >7 drinks. One drink is equivalent to 12 grams (g) of
alcohol: 12 ounces (360 milliliter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5
ounces (45 mL) of 80 proof distilled spirits.

- History of drug abuse or dependence within 6 months of the study.

- History of sensitivity to heparin or heparin-induced thrombocytopenia.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or medical
monitor, contraindicates their participation.

- Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test
result at screening or within 3 months prior to first dose of study treatment.

- A positive pre-study drug/alcohol screen.

- A positive test for human immunodeficiency virus (HIV) antibody.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within 56 days.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.